Home Healthcare Global Brain Tumor Diagnosis And Therapeutics Market
global brain tumor diagnosis and therapeutics market

Brain Tumor Diagnosis and Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Primary {Meningiomas, Gliomas, Astrocytoma’s, Pituitary Tumors, Others}, Secondary); By Diagnosis; By Therapeutics; By Region; Segment Forecast, 2022 - 2030

  • Published Date: Jul 2022
  • Pages: 115
  • Format: PDF
  • Report ID: PM1308
  • Base Year: 2021
  • Historical Data: 2018-2020

Report Summary

The global brain tumor diagnosis and therapeutics market was valued at USD 2.78 billion in 2021 and is expected to grow at a CAGR of 10.3% during the forecast period. Rising cases of brain tumors and significant advancements in the diagnosis capabilities are prime favoring the cancer diagnosis market growth.

Brain Tumor Diagnosis and Therapeutics Market Size
Know more about this report: Request for sample pages

According to the National Cancer Institute, 25,050 new brain tumor cases are estimated in 2022, with a 1.3% increase in the new cancer cases and an estimated 18,280 deaths in 2022, coupled with a 3.0% increase in brain tumor mortality.

The diagnosis for brain tumors depends upon several factors, like age, overall well-being, the size of the tumor, the stage at which it is medically diagnosed, the body area where it is diagnosed, and the type of tumor. However, the increasing cost of disease treatment and therapeutics along with the secondary effects of brain therapeutics are projected to hamper the brain tumor diagnosis and therapeutics market development during the forecast period.

Industry Dynamics

Growth Drivers
The viability of peptide-based therapeutics turned out to be notable to the medical care market with the approach of insulin therapeutics, and peptide-based drug conveyance was acquainted with the disease therapeutics market. Execution of peptide medications and peptide therapeutics in the malignant tumor diagnosis and therapeutics scene has developed strikingly in a couple of years, and consolidating peptide-based drugs in chemotherapy has become a promising method for further market developing the viability of disease therapeutics.

Partners in the malignant brain tumor diagnosis and therapeutics market are supporting examination into novel conveyance moved toward that incorporate joining peptide antibodies, peptide-based drugs, peptide-based therapeutics, and peptide-formed nanomaterials in disease care to present imaginative and more proficient disease medicines. Besides, with the continuous exploration and clinical examinations in customized meds for the diagnosis of malignant tumors, another window of chance will probably open for peptide-based medications and peptide-based therapeutics in the disease therapeutics market.

Report Segmentation

The market is primarily segmented based on type, diagnosis, therapeutics, and region.

By Type

By Diagnosis

By Therapeutics

By Region

  • Primary
    • Meningioma
    • Gliomas
    • Astrocytomas
    • Pituitary Tumors
    • Others
  • Secondary

 

  • MRI
  • CT Scan
  • Tissue Sampling
  • PET-CT scan
  • Cerebral Arteriogram
  • Lumbar Puncture
  • Molecular Testing
  • EEG
  • Others
  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Russia, Spain)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

PC Tomography market segment is expected to witness the fastest growth

PC Tomography (CT) market segment is supposed to observe rewarding development during the estimated time frame. It shows higher effectiveness in conveying portions of disease tissue-harming radiation than traditional X-beams. This increases the utilization of CT checks for diagnosing sicknesses. Moreover, this filtering rate per individual is roughly multiple times more noteworthy, guaranteeing the section's rewarding development over the estimated period. Likewise, drives taken by different states overall to bring issues to light to brain tumor pervasiveness and determination are supposed to influence diagnosis development emphatically.

MRI follows the CT examine fragment and is supposed to enlist productive market development over the projected period. Various nervous system specialists use these gadgets due to their precision in the examination. Besides, they likewise give nitty gritty pictures of the life systems of the brain, helping in precisely recognizing the area of conceivable dangerous tissue. The combination of CT examination with PET innovation (PET-CT scan) is utilized when examining protuberances while a patient is going through therapeutics. The PET-CT check is frequently used for finding when a CT sweep and MRI can't give sufficient data.

Primary brain tumors market segment holds the most significant market share

The primary brain tumor market section represented a considerable portion. Along all sub-portions, meningioma is generally common across the world, including the Asia Pacific and Europe. In these two locales, CNS and brain tumors are the third most normal disease among youthful grown-ups and adolescents.

Surgeries market segment is expected to hold the significant revenue share

Based on therapeutics, the medical procedures/surgeries market segment are expected to contribute the most substantial income to the brain cancer diagnosis and therapeutics market. The low awareness levels and limited diagnosis choices prompting irritation of the sickness to grade IV stage are supposed to support the interest in medical procedures.

Immunotherapy is the diagnosis of illness by actuating or stifling the invulnerable framework. Immunizations are a promising new type of immunotherapy that invigorates the safe framework for diagnosis of malignant tumors. The utilization of immunotherapy in glioblastoma multiforme, the most widely recognized primary harmful brain tumor in grown-ups, has been viewed as powerful.

AstraZeneca's AZD 1390 is a profoundly powerful brain penetrant Ataxia telangiectasia freak kinase inhibitor that blocks ATM sub-ordinate flagging and fixes DNA twofold strand breaks (DSBs) in the genome. This is client advancement by AstraZeneca for the diagnosis of brain tumors. Accordingly, the rising R&D drives to create immunotherapeutics to treat brain cancers and non-stop help from the public authority specialists to foster the opportunity diagnosis are projected to fuel the market development over the projected period.

The rising cases in North America are expected to witness significant growth

Geographically, North America is expected to showcase the most considerable market growth during the forecast period. Created medical care framework, more noteworthy per capita medical services spending, and nearly higher awareness concerning trendsetting innovations are sure to affect delivering factors.

This predominance is basically because of the elements, for example, the enormous number of individuals determined to have brain cancer, broad, innovative work exercises, mechanical progressions, and expanding medical diagnosis services awareness about the therapy and the executives of brain tumor diagnosis and therapeutics are driving business sector development.

Europe is anticipated for a high CAGR among all areas during the projected period, acquiring significant interest from the nations of Germany and The U.K. with the rising commonness of brain tumor sickness, heightening the level of geriatrics among the European populace, and the government's drive for developing attention to trendsetting diagnosis innovations are a portion of the key variables driving the brain tumor diagnosis and therapeutics market in Europe.

Competitive Insight

Some major market players operating the diagnosis market include Amgen Inc., AstraZeneca., Bayer AG, Bristol-Myers Squibb Co, Carestream Health, Inc., Eisai Inc., F. Hoffmann-La Roche Ltd, Fujifilm Corporation, GE Healthcare Inc., GlaxoSmithKline PLC, Hitachi, Pfizer Inc., Philips Healthcare, Shimadzu Corporation, Siemens Healthineers, and Toshiba Corporation.

Recent developments

  • According to the Columbia University Herbert Irving Comprehensive Cancer Center, the clinical trial performed on the new class of anti-brain cancer drugs, Selinexor, can shrink the recurrent glioblastomas (brain cancer) in almost every third patient.
  • In May 2022, Scientists at the University of Michigan Rogel Cancer Center developed a nanoparticle, a small molecule inhibitor, AMD3100, for blocking the action of the CXCR12 cytokine in the brain tumor. This cytokine prevents the immune system from attacking the glioma cells.
  • In November 2016, Toshiba Corporation sent off another Vantage Galan 3T MR examine, a high-level imaging method that worked on excellent imaging, which tracks down the high application in neurological malignant growth conclusion.

Brain Tumor Diagnosis and Therapeutics Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 2.78 billion

Revenue forecast in 2030

USD 6.60 billion

CAGR

10.3% from 2022 - 2030

Base year

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Segments covered

By Type, By Diagnosis, By Therapeutics, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Amgen Inc., AstraZeneca., Bayer AG, Bristol-Myers Squibb Co, Carestream Health, Inc., Eisai Inc., F. Hoffmann-La Roche Ltd, Fujifilm Corporation, GE Healthcare Inc., GlaxoSmithKline PLC, Hitachi, Pfizer Inc., Philips Healthcare, Shimadzu Corporation, Siemens Healthineers, and Toshiba Corporation.

Key Take-Away
Polaris Market Research
Global Brain Tumor Diagnosis and Therapeutics Market Size Report, 2022 - 2030